Keeping an Eye on What Really Matters!
With HYLO®, you don’t have to sacrifice patient welfare to help save on prescribing budgets, so you can keep an eye on what really matters.
See how HYLO-Tear and HYLO-Forte compare with other seemingly ‘cost saving’ eye lubricants in terms of:
i) Average duration of scripts and
ii) Annual costs to a PCN per patient:
Avoiding a 360o Switch
Real world PCN experience has shown that switching away from HYLO to other lower ‘cost saving’ eye lubricants has resulted in a switch back to HYLO’s due to increased usage and patient feedback.
Barnsley CCG: Switched from HYLO Forte to Evolve HA
Area Prescribing Committee minutes:
March 2019 – ‘The Lead Pharmacist, BHNFT had received 2 new product applications for preservative free Evolve preparations which were significantly more cost effective. As this was a brand switch and not a new product, the Committee agreed that the Evolve® Carmellose Eye Drops and Evolve® Hypromellose Eye Drops would be added to the Dry Eye Guideline, currently being reviewed. The Dry Eye Guidance would be brought to the next APC meeting and on approval; these products would be added to the formulary.’ Source
September 2019 – ‘The Head of Medicines Optimisation provided feedback from the LMC regarding issues relating to Evolve eye drops. Patients are requesting supplies more frequently as they are using larger quantities than stated dose, possibly due to the container. This would be fed back to the specialists.’ Source
Delivering Innovation With The HYLO® Range
We Are Here To Listen
Your Scope Eyecare Business Development Manager is on hand to support you making the right decisions that can benefit both your practice/PCN and your patients. They are also on hand to answer any questions you may have about HYLO®.
Leave a message and we give you a call-back
- Data on File – InspireMed, Preservative Free Sodium Hyaluronate Prescription Data, August 2021
- Data on file – Preservative free (PF) ocular lubricant data extracted from Cegedim’s THIN database, Jan 2020-Dec 2020 (Representative of 400+ GP practices & 3.2M patient population)
- TFOS DEWS II Management and Therapy Report. L. Jones et al. 2017, The Ocular Surface 15, pp. 575-628.
- The use of preservatives in dry eye drops. Karen Walsh, Lyndon Jones. Clinical Ophthalmology 2019:13 1409-1425